Head-To-Head Comparison: Exicure (NASDAQ:XCUR) vs. Zealand Pharma A/S (OTCMKTS:ZLDPF)
by Tristan Rich · The Markets DailyExicure (NASDAQ:XCUR – Get Free Report) and Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership.
Insider & Institutional Ownership
42.8% of Exicure shares are held by institutional investors. 52.8% of Exicure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
Exicure has a beta of 3.63, indicating that its share price is 263% more volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.
Earnings and Valuation
This table compares Exicure and Zealand Pharma A/S”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Exicure | $500,000.00 | 18.01 | -$4.95 million | ($1.32) | -1.04 |
| Zealand Pharma A/S | $1.40 billion | 2.38 | $977.29 million | $6.03 | 7.69 |
Zealand Pharma A/S has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Exicure and Zealand Pharma A/S’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Exicure | N/A | -237.91% | -61.98% |
| Zealand Pharma A/S | 58.86% | 18.53% | 17.14% |
Analyst Ratings
This is a summary of current ratings and recommmendations for Exicure and Zealand Pharma A/S, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Exicure | 1 | 0 | 0 | 0 | 1.00 |
| Zealand Pharma A/S | 1 | 8 | 1 | 1 | 2.18 |
Summary
Zealand Pharma A/S beats Exicure on 10 of the 14 factors compared between the two stocks.
About Exicure
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.